Matthew S Davids MD MMSc

PubMed

• Investigating the influence of germlinevariants in chronic lymphocytic leukemia on cancer vulnerability.
  Roberta S Azevedo, Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva
  Haematologica. 2025-04-01
• Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1q.
  Romanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, Junko Tsuji, Jean-Baptiste Alberge
  Blood. 2025-03-12
• BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.
  Stephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, Timothy Z Lehmberg, Jie Qing Eu
  Molecular Cancer. 2025-03-03

Journal Articles

• The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL  
  Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

• Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all

Other

• The Rise of Apoptosis: Targeting Apoptosis in Hematologic Malignancies 
  Matthew Davids, MD, Blood
  https://www.doximity.com/articles/98c8dcba-e43a-4f7a-a7f7-4f3bd29ea5d9
  UpToDate, Wolters Kluwer Health - 2013-03-29